Dataset Information

An Increased Frequency in HLA Class I Alleles and Haplotypes Suggests Genetic Susceptibility to Influenza A (H1N1) 2009 Pandemic: A Case-Control Study.

ABSTRACT: The influenza A H1N1/09 pandemic infected a small number of exposed individuals, which suggests the involvement of genetic factors. There are scarce data available on classical HLA class I association with the influenza A H1N1/09 pandemic.We analyzed the frequency of classical HLA class I alleles and haplotypes in A H1N1/09 influenza in a case-control study including 138 influenza patients (INF-P) and 225 asymptomatic healthy contacts (INF-C) simultaneously recruited. HLA class I typing was performed by high-resolution sequence-based typing method.Our analysis revealed higher frequency of C?07:02:01, B?39:06:02, C?03:02:01, B?44:03:01, B?51:01:05, and B?73:01 (p < 0.05; OR?=?1.84-9.98) and of two haplotypes-A?68:01:02-C?07:02:01 (p = 1.05E - 05; OR?=?23.99) and B?35:01:01-C?07:02.01 (p = 4.15E - 04, OR?=?2.15)-in A H1N1/09 influenza subjects. A?68:01:01 was exclusively present only in the INF-P group (5/138). A decrease in the frequency of C?03:03:01, A?11:01:01, B?39:01:01, A?24:02:01, C?03:04:01, B?51:01:01, and C?07:01:01 (p < 0.05; OR?=?0.12-0.52) and of haplotypes A?02:01:01-B?35:01:01-C?04:01:01, A?24:02:01-B?35:01:01, B?39:01:01-C?07:02:01, and B?40:02:01-C?03:04:01 (p < 0.05; OR?=?0.08-0.22) were observed in INF-P group.Selective classical HLA class I allele and haplotype combinations predispose individuals towards susceptibility or protection against the influenza A H1N1/09 pandemic. This work has significant implications for accessing population transmission risk for A H1N1/09 or a similar strain breakout in the future.

SUBMITTER: Falfan-Valencia R

PROVIDER: S-EPMC5845504 | biostudies-other | 2018

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

An Increased Frequency in HLA Class I Alleles and Haplotypes Suggests Genetic Susceptibility to Influenza A (H1N1) 2009 Pandemic: A Case-Control Study.

Falfán-Valencia Ramcés R Narayanankutty Arun A Reséndiz-Hernández Juan M JM Pérez-Rubio Gloria G Ramírez-Venegas Alejandra A Nava-Quiroz Karol J KJ Bautista-Félix Nora E NE Vargas-Alarcón Gilberto G Castillejos-López Manuel D J MDJ Hernández Andrés A

Journal of immunology research 20180225

<h4>Background</h4>The influenza A H1N1/09 pandemic infected a small number of exposed individuals, which suggests the involvement of genetic factors. There are scarce data available on classical HLA class I association with the influenza A H1N1/09 pandemic.<h4>Methods</h4>We analyzed the frequency of classical HLA class I alleles and haplotypes in A H1N1/09 influenza in a case-control study including 138 influenza patients (INF-P) and 225 asymptomatic healthy contacts (INF-C) simultaneously rec ...[more]

PMID: 29682588

Similar Datasets

Project description:Because many Aboriginal Canadians had severe cases of pandemic (H1N1) 2009 influenza, they were given priority access to vaccine. However, it was not known if the single recommended dose would adequately protect people at high risk, prompting our study to assess responses to the vaccine among Aboriginal Canadians.We enrolled First Nations and Métis adults aged 20-59 years in our prospective cohort study. Participants were given one 0.5-mL dose of ASO3-adjuvanted pandemic (H1N1) 2009 vaccine (Arepanrix, GlaxoSmithKline Canada). Blood samples were taken at baseline and 21-28 days after vaccination. Paired sera were tested for hemagglutination-inhibiting antibodies at a reference laboratory. To assess vaccine safety, we monitored the injection site symptoms of each participant for seven days. We also monitored patients for general symptoms within 7 days of vaccination and any use of the health care system for 21-28 days after vaccination.We enrolled 138 participants in the study (95 First Nations, 43 Métis), 137 of whom provided all safety data and 136 of whom provided both blood samples. First Nations and Métis participants had similar characteristics, including high rates of chronic health conditions (74.4%-76.8%). Pre-existing antibody to the virus was detected in 34.3% of the participants, all of whom boosted strongly with vaccination (seroprotection rate [titre ? 40] 100%, geometric mean titre 531-667). Participants with no pre-existing antibody also responded well. Fifty-eight of 59 (98.3%) First Nations participants showed seroprotection and a geometric mean titre of 353.6; all 30 Métis participants with no pre-existing antibody showed seroprotection and a geometric mean titre of 376.2. Pain at the injection site and general symptoms frequently occurred but were short-lived and generally not severe, although three participants (2.2%) sought medical attention for general symptoms.First Nations and Métis adults responded robustly to ASO3-adjuvanted pandemic (H1N1) 2009 vaccine. Virtually all participants showed protective titres, including those with chronic health conditions.

Dataset Information

An Increased Frequency in HLA Class I Alleles and Haplotypes Suggests Genetic Susceptibility to Influenza A (H1N1) 2009 Pandemic: A Case-Control Study.

Publications

An Increased Frequency in HLA Class I Alleles and Haplotypes Suggests Genetic Susceptibility to Influenza A (H1N1) 2009 Pandemic: A Case-Control Study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets